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ABSTRACT 
Objective: To evaluate if pharmacy students’ participation in personal pharmacogenetic (Pgx) testing enhances their knowledge and 
attitude towards precision medicine (PM). 
Methods: First-year pharmacy students were offered personalized pharmacogenetic testing as a supplement to a required curricular 
pharmacogenomics course. Ninety-eight of 122 (80%) students completed pre- and post-course surveys assessing knowledge and 
attitudes regarding PM; 73 students also volunteered for personal pharmacogenetic testing of the following drug metabolizing 
enzymes (CYP2C19, CYP2D6, UGT1A1) and pharmacodynamics-relevant proteins (interleukin (IL)-28B & human lymphocyte antigen 
HLAB*5701). 
Results: Among the 122 students, we found that incorporating pharmacogenetic testing improved mean knowledge and attitude by 
1.0 and 0.3 Likert points, respectively. We observed statistically significant improvements in 100% of knowledge and 70% of attitude-
related statements for students who decided to undergo personal pharmacogenetic testing. Students who were enrolled in the course 
but did not partake in personalized pharmacogenetic testing had similar gains in knowledge and attitude.  
Conclusion: This study demonstrates the feasibility and importance of educating future pharmacists by incorporating pharmacogenetic 
testing into professional school curricula. Students who opt not to participate in genotyping may still benefit by learning vicariously 
through the shared learning environment created by genotyped students.  
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INTRODUCTION 
Precision Medicine centers around combating human diseases 
through prevention and treatment based on lifestyle, 
environment and genetics, a theme embodied by President 
Obama’s Precision Medicine Initiative.1 To increase the 
acceptance of precision medicine in clinical practice, we must 
educate future healthcare providers and clinicians. A number 
of studies2–10 regarding the inclusion of pharmacogenomics-
related education in professional school curricula suggest 
promise. Unfortunately, the uptake into U.S. pharmacy 
programs has been reported as low. In 2010, Murphy et al. 
surveyed the number of hours U.S. pharmacy schools were 
dedicating to pharmacogenomics-related education. Only 
14.5% of the respondents spent between 31-60 hours on 
pharmacogenomics-related topics, and 61.3% of respondents  
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described the present state of pharmacogenomics instruction 
at most schools of pharmacy as “poor.”11  
 
Efforts at using genotyping as a teaching technique have been 
described,2,4,7–10 catalyzing the movement towards the 
adoption of pharmacogenomics into professional school 
curricula. Our study aims to add to this body of knowledge by 
providing personal pharmacogenetic testing to first year 
pharmacy students as an adjunct to a curricular 
pharmacogenomics course and examining the impact on 
knowledge and attitude. Innovations in this project include: (1) 
students having the autonomy to choose the most relevant 
gene to have genotyped based on their race or personal desire; 
(2) focusing solely on pharmacogenetic variants, avoiding 
potential controversy that some direct-to-consumer tests face 
when providing disease risk assessments; and (3) utilizing 
students to lead the initiative. 
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METHODS 
Initial Pilot 
Prior to our current assessment, a smaller pilot study was 
conducted among first-year doctor of pharmacy (PharmD) 
students in Biopharmaceutical Sciences (BPS) 115 (“Genetics 
and Pharmacogenetics”), a required pharmacogenomics 
course in the PharmD curriculum. Objectives for BPS 115 were 
broadly based and derived from components of genetic 
competencies put forth by the Accreditation Council for 
Pharmacy Education.12 In the Spring 2013 offering, twenty-two 
students volunteered to have their DNA isolated from blood 
samples and genotyped for variants in CYP2C19, a common 
drug metabolizing enzyme that is important in metabolizing 
several therapeutic agents, including clopidogrel, a widely 
used anti-platelet agent. The course directors chose to 
genotype CYP2C19 because variants in this gene are known to 
vary by race, and aside from the ability to metabolize certain 
drugs, the variants are not known to convey disease risk. This 
circumvents potential ethical issues that may arise when 
disclosing disease risk. Some universities offering genomic 
testing for genetic diseases have been criticized for failing to 
provide genetic counseling or conducting testing in a non-CLIA-
certified laboratory.13 
 
The BPS 115 course directors held a lecture session to disclose 
the results of the students’ genotypes. During this session, 
course directors reviewed the clinical implications in terms of 
drug metabolism of different variants of CYP2C19. Following 
the session, students organized a discussion session to ask 
faculty more questions and create a space for students to 
continue sharing their learning and genotypic information with 
other interested classmates. Twenty-two students 
participated. During this session, students were asked to 
provide their perceptions/beliefs and attitude regarding the 
experience, which was recorded in a session transcript taken 
by a student volunteer and utilized to help develop a formal 
study protocol. Students unanimously expressed the value of 
the testing and use of the results as teaching material for the 
course. Students discussed why it was compelling and crucial 
to their future as pharmacists and the future of their 
profession. A sample of representative, unsolicited student 
comments regarding their experience include: 
 
• “I see personal pharmacogenetic testing in the future 
of pharmacy. It can be time saving. It is going to be 
dependent on factors like whether MDs are willing to 
order genotyping tests instead of starting empirical 
therapy and dosing, and if we will begin educating our 
future clinicians. Implementation will require a new 
generation of MDs/pharmacists to lead this 
movement.” 
 
• “Information outside of academia regarding 
pharmacogenomics is limited. Many people in the 
public are not aware that testing is even available. As 
leaders/graduates from this university, we have to 
communicate our knowledge to outside communities 
and the rest of the world. Having a diverse group of 
people communicating this information will spread 
the word about needing research in more ethnically 
diverse populations. Pharmacists will be the most 
easily accessible group of healthcare practitioners, so 
questions about testing will go to us before many in 
the hospital.” 
 
• “I genuinely enjoyed the class, and I learned a lot. This 
information inspires me to want to look further into 
why certain populations are fast metabolizers, or slow 
metabolizer or do not respond well to certain 
medications. I would like to personally be involved in 
pharmacogenomics in the future during my career.” 
 
Survey Design  
Based on feedback from the pilot study, optional personal 
pharmacogenetic testing was incorporated into BPS 115 the 
following year. The overall design, implementation and 
completion of this project was led by three UCSF students; two 
were members of the School of Pharmacy and one was a 
graduate PhD student. Their tasks included interpreting 
feedback from the pilot trial, designing the pre- and post-
course surveys, submitting a protocol for approval through 
UCSF’s institutional review board (IRB) committee, analyzing 
the data and authoring the manuscript. BPS 115 has been a 
part of the core UCSF School of Pharmacy curriculum for 12 
years. Based on feedback from the pilot trial, the BPS 115 
instructors decided to incorporate voluntary personal 
pharmacogenetic testing during the Spring 2014 term. 
 
A pre-post design was used to evaluate student response.  
Survey development was informed by the group discussion 
session following the Spring 2013 BPS 115 class. We used 
students’ responses to identify topics for questions to assess 
students’ attitudes and knowledge towards precision 
medicine. A draft of the survey was then piloted among a 
sample of second-year pharmacy students; these results were 
used to refine the survey statements. First-year students were 
excluded from the design process to avoid influencing them 
during the actual assessment. The final survey included six 
knowledge statements, ten attitude statements and eight 
evaluative statements, which appeared only in the post-
intervention instrument.  (Full instrument available from 
authors on request.)  We chose a Likert-based response format 
because its common use lends itself to easy understanding by 
respondents, and answers can easily be quantified and used in 
statistical tests.  
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One month before the start of the term, an online Likert survey 
was administered to 122 first-year UCSF School of Pharmacy 
(SOP) students enrolled in BPS 115. The survey was re-
administered to the same first-year students following 
completion of the 10-week course. In addition to knowledge- 
and attitude-assessment statements in the post-course 
survey, additional evaluative statements were rated, allowing 
further assessment of students’ opinions about participating in 
pharmacogenetic testing.  
 
Expected outcomes included: (1) increased understanding of 
pharmacogenetic concepts in relation to clinical applications, 
(2) changes in attitudes toward precision medicine and clinical 
integration of pharmacogenetics, and (3) reports of enhanced 
learning. 
 
Survey Administration 
The UCSF Committee on Human Research approved the pre- 
and post-course survey and pharmacogenetic testing. Student 
coordinators visited the classroom before and after instruction 
to obtain written consent and email addresses from all 
students who were interested in participating in the survey. 
Email addresses were entered into UCSF’s Research Electronic 
Data Capture (REDCap14) system (REDCap, Nashville, 
Tennessee), a secure online utility for conducting surveys. 
Once a student logged on to REDCap using their email address, 
an anonymized, unique identifier was automatically generated 
and linked to login information. The same identifier was 
associated with all subsequent surveys, ensuring that no 
surveys were lost due to individuals forgetting their own self-
assigned survey numbers. 
 
While the REDCap survey system collected some basic 
personal information (e.g., name and UCSF email), it only 
exported the assigned anonymous identifier with the survey 
data. Researchers and course faculty members were restricted 
from accessing the names and email addresses associated with 
the survey results, helping to ensure that participation was 
voluntary. In addition, only the researchers were authorized to 
access the de-identified REDCap data; course directors were 
not involved in the survey-based assessment. 
 
Pharmacogenetic Testing 
BPS 115 students had the opportunity to volunteer to have 
their DNA genotyped for several drug-metabolizing enzymes 
as a “hands-on” personal pharmacogenetic learning 
experience. Several days were coordinated to collect de-
identified saliva samples from students. The samples were 
analyzed in a UCSF-affiliated CLIA-certified laboratory at San 
Francisco General Hospital at the rate of $50 per genotype. For 
the 73 students participating, the total genotyping cost was 
$3,650, which excludes time donated by laboratory staff to 
analyze the samples. The UCSF School of Pharmacy covered 
genotyping costs. Since genotyping was not performed 
through a commercial supplier, the results were ready sooner 
than the 3-6 week turnaround time often seen with direct-to-
consumer genetic testing companies. The total time student 
coordinators spent on participant consent and recruitment, 
DNA collection, and presentation of the data was 
approximately 140 person-hours. Students were given the 
option to be genotyped for a gene encoding a drug 
metabolizing enzyme (CYP2C19, CYP2D6, or UGT1A1) or a 
pharmacodynamics-relevant protein (IL28B or HLAB*5701). 
Each of the genes coding these enzymes/proteins has its own 
unique clinical implication and varying allele frequency (and 
therefore varying activity) among ethnic groups (Table 1).  
 
Once genotyping was completed, students were given their 
personal pharmacogenetic information during a regularly 
scheduled, 120-minute class period for BPS 115.  The class 
session was divided into two parts. During the first part, a 
pharmacogeneticist was invited to review and discuss each of 
the genes under evaluation, their variants, clinical significance, 
and methods for incorporating the information into clinical 
practice.  Five cases were used to illustrate clinical significance 
of the 5 genotyped genes. Topics included relevant 
information pertaining to the given gene and relevant drugs, 
such as irinotecan metabolism (UGT1A1), hepatitis C therapies 
(IL28b), and Steven Johnson’s syndrome (HLAB*5701). At the 
end of this discussion, the pharmacogeneticist displayed each 
of the possible genes via PowerPoint slides and revealed each 
of the possible variants. Next to each variant was a list of 
anonymized identifiers so that students were able to privately 
determine their individual genotype status. The first part of 
the session was didactic, while the second half of the session 
emphasized an active learning classroom model. Students 
were given 15 minutes to discuss the cases presented by the 
pharmacogeneticist together, and then initiated an open 
discussion about how different variants may affect 
pharmacologic or medical management. Students based many 
of their questions and comments on their personal 
pharmacogenomic data, as they discussed potential 
pharmacologic alternatives and interventions (e.g., dose 
reductions, discontinuation of medications, drug-drug 
interactions) to account for potential variants. Additionally, 
students expressed interest in strategies for pharmacists to 
play a more active role in the future of this specialty. This 
session did not require specific preparatory work besides 
attending the course lectures and completing assigned 
readings15–17 pertaining to the course and basic concepts of 
pharmacogenetics.  
 
Analysis 
We defined our outcome as change in knowledge or attitude 
regarding precision medicine. Specifically, we assigned integer 
values to the 5-point Likert scale (i.e., 1 = strongly disagree,  
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2 = disagree, 3 = neutral, 4 = agree and 5 = strongly agree) and 
then for each respondent, averaged over all knowledge-
related questions, separately for pre- and post-course surveys. 
This procedure was repeated for attitude-related questions, 
yielding 4 values for each respondent: pre-course means for 
knowledge and attitude, as well as post-course means for 
knowledge and attitude. Thus, our data set was structured in 
long format as follows: rows represented individual 
observations—each subject was represented twice (once for 
pre-course data, and again for post-course data); columns 
represented responses to individual Likert questions; a 
separate column represented time (pre-course versus post-
course); the last 2 columns represented the mean of 
knowledge- and attitude-related questions for a given 
individual (row).  
 
We used linear regression to estimate the effect of 
participating in BPS 115 on change in mean Likert scores for 
knowledge and attitude. Specifically, we used our pre/post 
indicator variable to predict the change in mean knowledge 
and mean attitude while controlling for sex and race. For 
example, a pre-survey response of 3 (neutral) followed by a 
post-survey response of 4 (agree) for mean knowledge would 
represent a gain of 1 Likert point. This change in mean served 
as our dependent variable. We assumed that the influence of 
time between the pre- and post-course surveys was negligible 
since measurements were made at the same time for all 
students. Our analysis was stratified into two groups: (1) 
students who participated in the personal genotyping and the 
survey (the genotyped group), and (2) those who participated 
in the survey, but not in personal genotyping (the non-
genotyped group). Estimates whose confidence intervals 
excluded the null value (0) were considered statistically 
significant at an alpha level of 0.05. Survey results were 
analyzed using the R statistical programming language (R Core 
Team, 2015).18  
 
RESULTS 
In total, 98 (80%) of the 122 students enrolled in the Spring 
2014 BPS 115 course voluntarily completed the pre- and post-
course surveys. Of these 98, 73 (74.5%) students also took part 
in genotyping, leaving 25 students (25.5%) to comprise the 
surveyed but not genotyped group. Selected demographic 
characteristics of the students are summarized in Table 2. 
Baseline scores in knowledge and attitude were similar for 
both groups. The mean baseline Likert score for knowledge 
statements was (3.03) in the genotyped group and (3.14) in the 
non-genotyped group. For the attitude statements, the mean 
baseline score was (3.85) in the genotyped group and (3.83) in 
the non-genotyped group. 
 
The results for change in mean knowledge and mean attitude 
for all students combined, and stratified by genotyping status, 
are summarized in Figure 1. By the end of the course, 
statistically significant increases were observed for mean 
knowledge (+1.0 Likert points) and mean attitude (+0.3 Likert 
points). The gain in mean knowledge was not significantly 
different between the genotyped (0.99) and non-genotyped 
(1.04) groups (p = 0.77). While the gain in mean attitude was 
slightly higher among those who did not participate in 
genotyping (0.34) versus those who did (0.29), the difference 
was not statistically significant (p = 0.74). The correlation 
between pre- and post-survey responses was fair for mean 
knowledge (Pearson’s r = 0.50) and mean attitude (r = 0.46).  
 
We also asked students to evaluate their experiences.  Table 3 
reports responses from the genotyped and non-genotyped 
groups. Changes in knowledge and attitude for specific 
questions are summarized in Table 4.  
 
DISCUSSION 
We found that incorporating genetic testing as an adjunct to 
the School of Pharmacy PharmD curriculum enhanced 
students’ self-reported knowledge and attitudes of precision 
medicine. We observed statistically significant increases across 
all knowledge assessment statements after the study. This 
finding provides support that an interactive hands-on 
approach to educating future pharmacists about 
pharmacogenetics is a curricular change that could benefit 
professional doctorate programs.  
 
Previous pharmacogenetics education efforts in schools of 
pharmacy4,7,9,10  and medicine2 have influenced our approach. 
Most recently in 2016, Adams et al.10 published results from 
the University of Pittsburgh demonstrating significant 
improvements in PharmD students’ knowledge and attitude 
after participating in personal pharmacogenetic testing 
through a commercial genotyping service. Since utilizing 
commercial services raised concerns about incidental findings 
of disease risk, we decided to eliminate this risk by focusing on 
genes that were solely pharmacogenetically relevant. 
Additional insight from the aforementioned literature that 
guided our approach included ensuring an interactive and 
hands-on approach2. For example, we sought to increase 
relevance and student interaction by allowing the selection of 
pharmacogenetic genes that may have been important to our 
students based on their ethnicity or personal interests.  
 
Our curricular approach to increasing knowledge and 
improving attitudes towards pharmacogenetic testing and 
precision medicine yielded encouraging results. The majority 
(80%) of students completed pre- and post-course surveys, 
and 74.5% took part in personal pharmacogenetic testing. 
Based on our experience, implementing personal 
pharmacogenetic testing in U.S. pharmacy school curricula 
need not be extremely arduous. Student participation was 
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very high in the absence of incentives; the time and effort 
dedicated toward collection and processing of DNA was fairly 
minimal; performing genotyping in-house was efficient and 
allowed for exclusion of disease-associated variants; and the 
discussion of genotyping results was limited to only one class 
session. Instructors could limit their selection of genetic tests 
to inexpensive ones to optimize widespread dissemination of 
an educational session of this type.  
 
One of our most noteworthy findings was in regard to 
Knowledge Statement #4 (Table 4): “I am aware of the types of 
knowledge and resources needed to interpret a 
pharmacogenetic test.” The reported change was fairly large 
among genotyped students, (1.32, 95%CI: 1.05-1.58), 
demonstrating that students felt confident utilizing their 
resources to interpret a pharmacogenetic test. This 
observation suggests that a curriculum designed to include 
similar personal pharmacogenetic testing may help prepare 
students to keep up with the precision medicine revolution. 
 
The gain in knowledge and attitude for both the genotyped 
and non-genotyped group is interesting and questions 
whether our results are attributable to personal 
pharmacogenetic testing versus traditional didactic 
coursework. The difference in improvement between groups 
is greater for the knowledge-related items than for attitude, 
consistent with the belief that knowledge affects attitude, 
which in turn affects behavior.19,20 The genotyped group had 
tighter confidence intervals and more robust data as we would 
have expected based on sample size. However, that both 
groups improved in knowledge and attitude is encouraging, 
suggesting that once participation in genetic testing surpasses 
some threshold, non-genotyped students may learn 
vicariously through experiences and learning environment 
created by genotyped students. In fact, 68% of non-genotyped 
students agreed or strongly agreed that their classmates’ 
participation in genotyping positively impacted their learning 
in the course (Table 3). In essence, the rising tide of 
pharmacogenetic education lifted all boats. 
 
Potential biases and limitations should be considered when 
reviewing the results of our study. Knowledge and attitude 
were measured by self-assessment. This method is not as 
robust as objective data (e.g., exam questions). Some 
unmeasured characteristics of genotyped students (e.g., 
attitudes toward providing biological samples) may have 
differed from non-genotyped students such that comparison 
of pre-post results between these groups could have been 
biased. However, we found no significant difference in 
baseline knowledge or attitude between the two groups. 
Given that the reported change for all knowledge and 9 out of 
10 of the attitude assessment statements were positive, 
regardless of genotyping status, we feel that the influence of 
this type of selection bias was minimal. Results for the non-
genotyped group may have been underpowered given the 
smaller number of students who chose not to be genotyped 
(25 versus 73). Our analyses were conducted under the 
assumption that the intervals between Likert values are equal. 
We felt it reasonable, for example, to assume that “Agree” is 
halfway between “Neutral” and “Strongly agree,” a common 
assumption practiced in analysis of survey results.21 Isolating 
the impact of genetic testing through an experimental design 
without overly disrupting the course structure posed logistical 
challenges. As with intervention trials, preventing crossover 
(e.g., non-compliance or contamination) between treatment 
groups would have been difficult—a common case in 
education-related studies. 
 
To overcome these limitations, a future cluster-based 
randomized study with several pharmacy school curricula 
could be implemented. Since self-efficacy—which was not 
measured in this study—is useful for predicting future 
behavior, we plan to contact these students for a long-term 
follow-up to assess the lasting effects that personal 
pharmacogenetic testing has had on their personal and 
professional lives.  
 
SUMMARY 
First-year PharmD students who volunteered to participate in 
personal pharmacogenetic testing showed statistically 
significant increases in self-reported knowledge and attitudes 
towards precision medicine. This increase was also observed 
among students who were enrolled in the course, but did not 
partake in personalized pharmacogenetic testing, likely a 
result of engagement with their classmates and faculty. This 
dynamic allows room for pharmacy schools to personalize the 
incorporation of pharmacogenetic testing into their curricula. 
 
Our study was comprised of three innovative elements: (1) 
providing students the autonomy to choose the most relevant 
gene for genotyping; (2) focusing solely on pharmacogenetic 
variants, avoiding potential controversy associated with some 
direct-to-consumer tests that also assess disease risk; and (3) 
utilizing students to lead the initiative. These three 
components may aid dissemination of similar projects at other 
institutions. 
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Table 1: Drug Metabolizing Enzymes, Function, and Variant Allele Frequencies 
Enzyme 
(reference) Function 
Variant Allele Frequency 
(decreased function) by 
Race 
CYP2D622–24 
Affects large numbers of drugs, notably analgesics, 
tamoxifen, and antidepressants and medications for 
attention deficit disorder. 
Black:0-5% 
Caucasian: 5-14% 
Asian: 0-1% 
CYP2C1923–25 
Affects cardiovascular drugs including clopidogrel and 
proton pump inhibitors and some antidepressant 
medications 
Black: 5% 
Caucasian: 2-5% 
Asian: 19% 
UGT1A126 Affects some anticancer drugs and is responsible for hyperbilirubinemia induced by Gilbert’s syndrome. 
Black: 19% 
Caucasian: 8% 
Asian: 2% 
HLAB*570127 When present can cause Stevens Johnson Syndrome and delayed hypersensitivity mostly among Asians. 
Black: 1% 
Caucasian: 6-7% 
Asian: up to 20% 
IL28b28 C/C Alleles predicts drug efficacy towards chronic Hepatitis C infections 
Black: 24-50% 
Caucasian: 8-13% 
Asian: 0-1% 
 
 
 
 
Table 2: Gender and Race/Ethnicity of Participants and Nonparticipants 
Characteristic Genotyped Group N = 73 
Non-Genotyped Group  
N = 25 
Percent female* 71.2 60.0 
Race/Ethnicity N (%) N (%) 
Hispanic 0 (0.0%) 1 (4.0%) 
Black 1 (1.40%) 1 (4.0%) 
White 15 (20.5%) 4 (16.0%) 
Asian 41 (56.2%) 17 (68.0%) 
Other 14 (19.2%) 2 (8.00%) 
Pacific Islander 2 (2.70%) 0 (0.00%) 
* P-value < 0.05  
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Table 3: Responses to Evaluative Statements from Genotyped and Non-Genotyped Groups 
 
Genotyped Group N = 73 
Question 
Strongly 
Disagree 
N (%) 
Disagree 
N (%) 
Neutral 
N (%) 
Agree 
N (%) 
Strongly Agree 
N (%) 
Glad to have participated in 
Pgx testing 0 (0%) 
 
2 (3.0%) 6 (8.0%) 
 
31 (42.0%) 34 (47.0%) 
I believe I have a better 
understanding of Pgx 
principles 
0 (0%) 1 (1.0%) 10 (14.0%) 37 (51.0%) 25 (34.0%) 
Felt more engaged because 
I had undergone Pgx testing 1 (1.0%) 2 (3.0%) 14 (19.0%) 26 (36.0%) 30 (41.0%) 
My participation reinforced 
concepts taught in BPS 115  1 (1.0%) 1 (1.0%) 10 (14.0%) 34 (47.0%) 27 (37.0%) 
 
Non-Genotyped Group N = 25 
Question 
Strongly 
Disagree 
N (%) 
Disagree 
N (%) 
Neutral 
N (%) 
Agree 
N (%) 
Strongly Agree 
N (%) 
I regret not participating in 
Pgx 0 (0%) 5 (20.0%) 5 (20.0%) 11 (44.0%) 4 (16.0%) 
Classmates’ Pgx results 
reinforced concepts 0 (0%) 1 (4.0%) 7 (28.0%) 14 (56.0%) 3 (12.0%) 
I am interested in 
participating in more 
comprehensive genetic 
tests 
0 (0%) 1 (4.0%) 7 (28.0%) 13 (52.0%) 4 (16.0%) 
If offered again, I would 
undergo Pgx testing 0 (0%) 2 (8.0%) 8 (32.0%) 9 (36.0%) 6 (24.0%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Student Project EDUCATION 
 
http://z.umn.edu/INNOVATIONS                          2017, Vol. 8, No. 1, Article 2                    INNOVATIONS in pharmacy   10 
 
Table 4: Knowledge and Attitude Assessment Questions from Pre and Post Survey 
 Genotyped (N=73)  Non-Genotyped (N=25)  
 Effect Size 95% CI Effect Size 95% CI 
Knowledge 
Change in mean knowledge  0.99 0.81-1.17 1.04 0.72-1.37 
1. I understand what precision medicine is. 0.64 0.42-0.87 0.84 0.41-1.27 
2. I understand what a pharmacogenetic 
test is. 0.89 0.67-1.11 1.20 0.78-1.62 
3. I understand how a pharmacogenetic test 
differs from a genetic test for disease risk. 1.18 0.92-1.44 0.96 0.42-1.50 
4. I am aware of the types of knowledge and 
resources needed to interpret a 
pharmacogenetic test result. 
1.32 1.05-1.58 1.08 0.59-1.57 
5. I understand how to evaluate the clinical 
validity and utility of a pharmacogenetic 
test. 
1.19 0.91-1.47 1.32 0.86-1.78 
6. I understand the risks, benefits, and 
ethical considerations of personal genetic 
testing. 
0.71 0.47-0.95 0.84 0.42-1.26 
Attitude 
Change in mean attitude 0.29 0.13-0.44 0.34 0.02-0.67 
1. The use of personal genetic information in 
health care is beneficial to patients. 0.29 0.08-1.25 0.20 -0.22-0.62 
2. The use of personal genetic information in 
health care may cause unnecessary harm 
to patients. 
-0.01 -0.32-0.31 0.18 -0.42-0.77 
3. In addition to factors like age, race, and 
drug interactions, genetic information is 
an important consideration during routine 
clinical practice. 
0.28 0.05-0.48 0.28 -0.13-0.69 
4. I would recommend pharmacogenetic 
testing for a patient. 0.49 0.26-0.65 0.48 0.01-0.95 
5. I would recommend pharmacogenetic 
testing for a family member. 0.47 0.25-0.62 0.44 -0.03-0.91 
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6. Pharmacogenetic testing, when 
applicable, should be integrated into 
patient care. 
0.47 0.26-0.70 0.50 0.09-0.90 
7. Pharmacists should be trained to 
interpret and apply pharmacogenetic test 
results. 
0.26 0.06-0.48       0.44 0.08-0.80 
8. Pharmacogenetics should be integrated 
into the curricula at all pharmacy schools. 0.34 0.12-0.55 0.48 -0.04-0.92 
9. Pharmacogenetics will likely play an 
important role in my future career. 0.09 -0.15-0.29 0.28 -0.17-0.73 
10. Pharmacists play a crucial role in the 
future of precision medicine. 0.18 -0.02-0.38 0.24 -0.17-0.65 
 
 
 
 
 
Figure 1: Overall Mean Change in Knowledge and Attitude 
 
 
 
